72017 3 資料 内分泌療法を受けている乳がん患者の苦痛体験に関する文献検討 A Literature Review regarding Distress Experienced by Breast Cancer Patients Undergoing Endocrine Therapy 四方文子 1), 鈴木久美 2) Ayako Shikata 1),Kumi Suzuki 2) キーワード : 内分泌療法, 乳がん, 苦痛体験, 文献検討 Key Words : endocrine therapy, breast cancer, distress, experience, literature review Ⅰ. はじめに 5 2015 702013 2013 2002 3 1 Ⅱ. 方法 1. 用語の定義 2. 検索方法および対象文献の選定 WebVer.5 oror 1) 大阪医科大学大学院看護学研究科,2) 大阪医科大学看護学部 137
72017 3 orororor oror 2006 2015 10 6120165 9 CINAHL breast cancerhormonal therapyorendocrine therapyortamoxifenorgoserelinside effectorsymptomexperienceordistress oranxietyordepressionorconcernor employed2006 201510 79 2016 5 11 表 1 3. 分析方法 Ⅲ. 結果 1. 内分泌療法を受けている乳がん患者の苦痛体験に関する研究の動向 表 2 2011 2 6 2. 内分泌療法を受けている乳がん患者の身体的苦痛 11 SMI 4No.18911 1No.14MDASIThe MD Anderson Symptom Inventory1No.2 表 3 1No.1 3 表 4 TAM AI No.8TAM ANA EXE No.1519 TAM EXE 12 No.18 QOL 138
72017 3 表 1 1 2015 QOL 29225-32 2 2015 Ochayon L, Tunin R, Yoselis A, et al. : Symptoms of hormonal therapy and social support: Is there a connection? Comparison of symptom severity, symptom interference and social support among breast cancer patients receiving and not receiving adjuvant hormonal, European Journal of Oncology Nursing, 25, 260-267 3 2015 Shoshana M, Rosenberg AL, Stantonb KJP, et al. : Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer, The Oncologist, 20, 598-604 4 2014 Shelby AR, Edmond NS, Wren AA, et al. : Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine, Support Care Cancer, 22, 2851-2859 5 2014 Londen GJ, Donovan SE, Beckjord BE, et al. : Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-Related Symptoms, 41(6), Oncology Nursing Forum, 660-668 6 2013 519-17 7 2013 27216-25 8 2013, 27113-20 9 2013 19139-44 10 2012 4223 172-175 11 2012 271102-103 12 2012 Mieog DJ, Morden PJ, Bliss MJ, et al. : Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study, Lancet Oncology, 13, 420-432 13 2012 Breckenridge ML, Bruns LG, Todd LB, et al. : Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors, Psycho Oncology, 21(1), 43-53 14 2010 QOLI4030-32 15 2010 Ochayon L, Zelker R, Kaduri L, et al.relationship Between Severity of Symptoms and Quality of Life in Patients With Breast Cancer Receiving Adjuvant Hormonal Therapy, Oncology Nursing Forum, 37(5), 349-358 16 2009 313-12 17 2009 Chin NS, Trinkaus M, Simmons C, et al. : Prevalence and Severity of Urogenital Symptoms in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer, Clinical Breast Cancer, 9(2), 108-117 18 2007 Jones ES, Cantrell J, Vukelja S, et al. : Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy Prevalence and Severity of Urogenital Symptoms in Postmenopausal Women Receiving Endocrine, J Clin Oncol, 25, 4765-4771 19 2006 The Arimidex, Tamoxifen, Alone or in Combination Trialists Group: Comprehensive sideeffect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial, Lancet Oncology, 7, 633-643 20 2006 Land RS, Wickerham LD, Costantino PJ, et al. : Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention, JAMA, 295(23), 2742-2752 43.2 5.4 61.8 7.3 29 85 24 86 63.7 58.8 6.7 60 80 37 49 37 75 52.5 8.4 36.5 1515 84 57 64 2,086 112 14 6 507 83 83 394 48 45 2,319 2,338 44.910.0 5411.6 31 93 31 50 60.510.8 40 90 649 35 75 77 56 70 132 15 251 806 808 3,092 3,094 973 1,010 139
72017 3 表 2 2006-2010 2011-2015 2 7 4 5 2 1 6 5 6 1 10 0 6 5 7 13 5 15 2 7 11 表 3 1 3 8 12 15 17 Shoshana Mieog D Ochayon LChin NS 2015 M et al. 2015 2013 et al. 2012 et al. 2010 et al. 2009 15 15 2,086 83 4,657 132 251 73.3 53.3 53.3 46.7 66.7 53.3 66.7 67.7 80.0 67.7 66.7 33.3 33.3 33.3 53.3 33.3 86.7 86.7 73.3 68.0 47.0 48.0 41.0 83.1 69.9 74.7 54.2 66.3 54.2 89.2 89.2 86.7 89.2 42.6 1.7 26.0 39.0 33.0 32.0 35.0 26.0 22.0 41.0 36.0 12.0 11.0 48.0 32.0 27.0 26.0 5.0 140
72017 3 表 4 TAM vs AI TAM TAM 815 AI AI TAM vs ANA TAM ANA TAM vs EXE TAM 12 EXE3 6 TAM vs RLX TAM SERM 19 1218 TAMAIANAEXE RLX 20 QOL 3 No.4QOL QOL No.1415 3. 内分泌療法を受けている乳がん患者の精神的苦痛 表 5 98 No.7 No.7 No.10 No.7 No.2 No.7 No.7 No.7 5No.18 13 15 No.1 3 No.13 QOL 2 No.114 QOL 4. 内分泌療法を受けている乳がん患者の社会的苦痛 表 6 11 7 No.5 No.15 141
72017 3 表 5 6 710 1518 714 27 716 5715 716 67 No.7 No.10 No.5 No.17No.151819 No.7 No.10 No.2 Ⅳ. 考察 1. 内分泌療法を受けている患者に関する研究の動向 2011 2000 2006 142
72017 3 表 6, 257 1315 6 16 7 510 1517 1819 71016 40 60 Alteri, et al.2015 2. 内分泌療法を受けている乳がん患者の体験している苦痛体験と援助 143
72017 3 QOL 3 QOL 3. 内分泌療法を受けている閉経前患者における苦痛体験と援助 3 QOL QOL 26 201430 40 5 4. 内分泌療法を受けている閉経後患者における苦痛体験と援助,,, 2013 Ⅴ. 結論 3 QOL 144
72017 3 QOL 20152-186 20152-11 2013 27113-20 31 引用文献 2013 119-130186-189 Alteri R, Bertaut T, Brinton AL, et al. (2015) : Breast Cancer Facts & Figures 2015-2016, American Cancer Society, 1-38. 2013http://ganjoho.jp/reg_stat/statistics/ stat/summary.html2016516 26 2014http://www.soumu.go.jp/ johotsusintokei/whitepaper/ja/h26/html/nc141210.html 20161026 2002 5011-18 2011http://www.jakunen.com/index.html2015 8 12 145